Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
BEFREE |
Fibroblast growth factor receptor-2 (<i>FGFR2</i>) gene is amplified in up to 15% of patients with gastric cancer (GC).
|
31258762 |
2019 |
Malignant neoplasm of stomach
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
The FGFR2-inhibitory activity of PRO-007 was confirmed in genetically modified GC cell lines.
|
31396354 |
2019 |
Malignant neoplasm of stomach
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, this meta-analysis indicates that FGFR2 overexpression is associated with poor pathological features and prognosis in patients with GC.
|
30662521 |
2019 |
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
BEFREE |
The aim of the present study was to explore the effects of miR‑494 and FGFR2 in regulation of cancer‑initiating cell phenotypes and therapeutic efficiency of lapatinib in HER2‑positive gastric cancer.
|
29786108 |
2018 |
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
BEFREE |
The in vivo models established using SGC cell lines are expected to serve as a useful tool for the development of drugs such as FGFR2 inhibitors, TβR inhibitors, and CXCR1 inhibitors, which might be promising as SGC treatments.
|
29876827 |
2018 |
Malignant neoplasm of stomach
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
In tumor cell lines displaying molecular alterations in potential nintedanib targets, the inhibitor demonstrates direct antiproliferative effects: in the NSCLC cell line NCI-H1703 carrying a PDGFR<i>α</i> amplification (ampl.); the gastric cancer cell line KatoIII and the breast cancer cell line MFM223, both driven by a FGFR2 amplification; AN3CA (endometrial carcinoma) bearing a mutated FGFR2; the acute myeloid leukemia cell lines MOLM-13 and MV-4-11-B with FLT3 mutations; and the NSCLC adenocarcinoma LC-2/ad harboring a CCDC6-RET fusion.
|
29263244 |
2018 |
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
BEFREE |
Fibroblast growth factor receptor (FGFR2) has been proposed as a target in gastric cancer.
|
28852882 |
2018 |
Malignant neoplasm of stomach
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
FGFR2 was shown to be markedly overexpressed in GC tissues and was correlated with a high risk of lymph node metastasis, late clinical stage, and poor prognosis.
|
30355943 |
2018 |
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
BEFREE |
Amplification of fibroblast growth factor receptor2 (FGFR2) has been regarded as a druggable target in gastric cancer (GC).
|
30044964 |
2018 |
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
BEFREE |
Recently, targeting FGFR2 has drawn attention as a form of gastric cancer therapy, and FGFR-selective inhibitors have shown promising efficacy in clinical studies.
|
30045926 |
2018 |
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
BEFREE |
In the current study, we aimed at revealing the function of DDX6 in HER2 and FGFR2 related human gastric cancer (GC) by using clinical samples and GC cell lines.
|
29987267 |
2018 |
Malignant neoplasm of stomach
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
There was no interaction between FGFR2 expression and patient survival outcomes in stage II/III gastric cancer.
|
29434882 |
2018 |
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
BEFREE |
FGFR inhibitors may function against FGFR2-amplified GC, and a novel FGFR2-ACSL5 fusion identified by transcriptomic characterization may underlie clinically acquired resistance.
|
28122360 |
2017 |
Malignant neoplasm of stomach
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
As a well-defined antagonist in FGFR2-induced RAS/ERK activation, ectopic expression of sprouty (SPRY) family was reported in several kinds of cancers except gastric cancer.
|
28002800 |
2017 |
Malignant neoplasm of stomach
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Approximately 5%-10% of gastric cancers have a fibroblast growth factor receptor-2 (FGFR2) gene amplification.
|
29177434 |
2017 |
Malignant neoplasm of stomach
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Subgroup analysis revealed that high fibroblast growth factor receptor 2 expression was also associated with poor prognosis of gastric cancer, hepatocellular carcinoma, and esophageal cancer, but not correlated with pancreatic cancer.
|
28618942 |
2017 |
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
BEFREE |
Using a three-dimensional organoid tissue model, we functionally validated the metastatic potential of an FGFR2 amplification in gastric cancer.
|
28629429 |
2017 |
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
BEFREE |
However, multivariate analysis indicated that FGFR2 amplification was not an independent prognostic factor for OS (HR=1.42, 95% CI: 0.77-2.61, p=0.261).Although FGFR2 amplification is associated with poorer OS, it does not appear to be an independent prognostic predictor in patients with advanced gastric cancer treated with palliative fluoropyrimidine and platinum chemotherapy.
|
27802183 |
2017 |
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
BEFREE |
Our findings suggest that FGFR2 amplification is a relevant therapeutic target in GC with peritoneal carcinomatosis.
|
28501555 |
2017 |
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
BEFREE |
FGFR2 in gastric cancer: protein overexpression predicts gene amplification and high H-index predicts poor survival.
|
27230412 |
2016 |
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
BEFREE |
FGFR1 is relatively frequently amplified and overexpressed in breast and lung cancer, and FGFR2 in gastric cancer.
|
27245147 |
2016 |
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
BEFREE |
In conclusion, CD44 and FGFR2 maintain stemness in gastric cancer by differentially regulating c-Myc transcription.
|
27107424 |
2016 |
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
BEFREE |
Similar results were obtained in additional GC cell lines with amplification of MET or the FGF receptor FGFR2 MKN45 murine xenograft experiments demonstrated the antitumor activity of M-COPA in vivo Taken together, our results offer an initial preclinical proof of concept for the use of M-COPA as a candidate treatment option for MET-addicted GC, with broader implications for targeting the Golgi apparatus as a novel cancer therapeutic approach.
|
27197184 |
2016 |
Malignant neoplasm of stomach
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Evaluation of Fibroblast Growth Factor Receptor 2 Expression, Heterogeneity and Clinical Significance in Gastric Cancer.
|
26516773 |
2015 |
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
BEFREE |
It will be clinically valuable to investigate the involvement of RTK-mediated signaling in intrinsicor acquired resistance to FGFR2 TKIs in GC.
|
25576915 |
2015 |